XSC
HRTX icon

X-Square Capital’s Heron Therapeutics HRTX Stock Holding History

X-Square Capital’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-31,185
Closed -$53K – 166
2023
Q4 		$53K Hold
31,185
– – 0.03% 153
2023
Q3 		$36K Hold
31,185
– – 0.02% 137
2023
Q2 		$36K Sell
31,185
-116,677
-79% -$208K 0.02% 137
2023
Q1 		$223K Hold
147,862
– – 0.13% 131
2022
Q4 		$370K Buy
147,862
+95,000
+180% +$306K 0.21% 117
2022
Q3 		$223K Hold
52,862
– – 0.14% 130
2022
Q2 		$147K Sell
52,862
-500
-0.9% -$2.01K 0.09% 141
2022
Q1 		$305K Hold
53,362
– – 0.16% 125
2021
Q4 		$487K Buy
53,362
+100
+0.2% +$1.02K 0.24% 100
2021
Q3 		$569K Sell
53,262
-3,999
-7% -$48.7K 0.29% 88
2021
Q2 		$889K Buy
57,261
+41,462
+262% +$660K 0.42% 72
2021
Q1 		$256K Buy
15,799
+4,399
+39% +$78.4K 0.12% 103
2020
Q4 		$241K Buy
11,400
+1,400
+14% +$24.3K 0.13% 99
2020
Q3 		$148K Hold
10,000
– – 0.11% 91
2020
Q2 		$147K Hold
10,000
– – 0.1% 86
2020
Q1 		$117K Buy
+10,000
New +$188K 0.12% 74

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

X-Square Capital's HRTX Position: Q1 2024 in Review

X-Square Capital sold out of Heron Therapeutics (HRTX) in Q1 2024, closing a stake of 31,185 shares — an estimated $53K sold.

X-Square Capital first reported a position in HRTX in Q1 2020 and held it in 16 quarters. The position peaked at $889K in Q2 2021. 161 funds tracked by Wall St. Rank hold HRTX as of Q1 2024.

  • X-Square Capital reported no remaining Heron Therapeutics position as of Q1 2024 after selling out during the quarter.
  • X-Square Capital sold 31,185 Heron Therapeutics shares in Q1 2024, an estimated $53K.
  • X-Square Capital first reported a position in Heron Therapeutics in Q1 2020 and held it in 16 quarters.
  • X-Square Capital's Heron Therapeutics position peaked at $889K in Q2 2021.
  • 161 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2024.

Based on X-Square Capital's 13F filing for Q1 2024, filed 14 May 2024.